![MSK’s Vickers: “We’ve been seen as exclusive and selected. I want to broaden that aperture for the organization.”](https://cdn.cancerletter.com/media/2023/02/17152851/49-07-Vickers-4x3-1.jpg)
![MSK’s Vickers: “We’ve been seen as exclusive and selected. I want to broaden that aperture for the organization.”](https://cdn.cancerletter.com/media/2023/02/17152851/49-07-Vickers-4x3-1.jpg)
Cover Story
Black History MonthCancer History Project
Selwyn M. Vickers wants Memorial Sloan Kettering Cancer Center to become better known in Harlem, Coney Island, and other parts of New York City where the elite institution he now leads is not a go-to place.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
Trending Stories
- Before the Olympics were smoke-free, tobacco brand deals ran rampant
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications
- Better oncology drug management could lead to improved outcomes, lower costs
- Tweaking the existing systems is not the answer to drug shortages